Suan Farma, a worldwide distributer for the production technology of statins from the Neuron Group
The Neuron Group and the Suan Farma company have signed a commercial agreement for the set up and commercialisation of an innovative statin- production technology. These drugs, which have the highest sales worldwide, are commonly used to decrease high levels of cholesterol thus reducing myocardial infarction and death by coronary failure.
Traditionally the synthesis of these kinds of compounds has been based on time consuming chemical processes, which involve numerous intermediate transformation phases, resulting in a high sales price to the public.
The new technology developed by the Neuron Group via its BioIndustrial division, allows the production of these drugs by a simple, economic and environmentally favourable process. The
Suan Farma company has agreed to commercialise this innovative technology.
Suan Farma is one of the most important companies to commercialise and distribute raw materials for the pharma and veterinary industries and it offers R&D services and production services for third parties in almost all areas of biotechnology.
The Neuron Group develops its research via three specialised divisions: BioPharma, BioIndustrial and agrofood via Innofood by Neuron. This new agreement is proof of the growth of the Neuron Group via partnerships with other leading companies in the fields of pharma, energy and agrofood focusing on the development of new products and with the aim of strengthening new commercial activities.